financetom
Business
financetom
/
Business
/
TELUS Health Expands Access to Public Primary Care in Ontario With Toronto Clinic
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TELUS Health Expands Access to Public Primary Care in Ontario With Toronto Clinic
Nov 12, 2024 6:03 PM

08:51 AM EST, 11/12/2024 (MT Newswires) -- Telus Health, a healthcare technology company that is part of Telus ( TU ) , on Tuesday said it has opened a new public health primary care clinic in Toronto.

The clinic will combine virtual healthcare technology with traditional in-person care. The Telus Health MyCare Union clinic, operating out of repurposed office space in downtown Toronto, is accepting up to 6,000 new patients with plans to expand in the future.

The company notes that 500,000 Toronto residents do not have access to a family doctor.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
DallasNews Files Proxy Statement for Proposed Buyout by Hearst
DallasNews Files Proxy Statement for Proposed Buyout by Hearst
Aug 18, 2025
08:03 AM EDT, 08/18/2025 (MT Newswires) -- DallasNews ( DALN ) said Monday it has filed a definitive proxy statement for its proposed acquisition by Hearst. Under Hearst's proposal, DallasNews ( DALN ) shareholders will receive $15 per share in cash, implying a premium of 242% over the company's last class A share price close of $4.39 before the proposal...
Soligenix Says Dusquetide Gets Orphan Drug Designation From US FDA to Treat Behcet's Disease
Soligenix Says Dusquetide Gets Orphan Drug Designation From US FDA to Treat Behcet's Disease
Aug 18, 2025
08:04 AM EDT, 08/18/2025 (MT Newswires) -- Soligenix ( SNGX ) said Monday that the US Food and Drug Administration has granted orphan drug designation to dusquetide for the treatment of Behcet's disease, an inflammatory disorder of the blood vessels. The decision was made after a review of the recent phase 2a clinical results showing biological efficacy and safety in...
Aptose Biosciences Reports Early Positive Tuspetinib Safety Data Across Newly Diagnosed AML Patients
Aptose Biosciences Reports Early Positive Tuspetinib Safety Data Across Newly Diagnosed AML Patients
Aug 18, 2025
08:01 AM EDT, 08/18/2025 (MT Newswires) -- Aptose Biosciences ( APTOF ) on Monday said the latest data update from the Phase 1/2 Tuscany trial in newly diagnosed acute myeloid leukemia (AML) patients show no significant safety concerns with different dose levels of the company's lead candidate, tuspetinib. The trial was initiated last December. Data from 10 patients across all...
Sunrun Likely to Offer Longer-Term Demand Visibility Due to US Treasury Guidance, RBC Says
Sunrun Likely to Offer Longer-Term Demand Visibility Due to US Treasury Guidance, RBC Says
Aug 18, 2025
08:01 AM EDT, 08/18/2025 (MT Newswires) -- Sunrun ( RUN ) is likely to offer longer-term demand visibility due to the US Treasury outlook, which will also help the company largely eliminate the uncertainty under President Trump's executive order for stringent Treasury guidance on enforcement of commerce construction rules, RBC said in a Monday note. The company's value proposition lies...
Copyright 2023-2026 - www.financetom.com All Rights Reserved